Elicera Therapeutics AB (publ) (STO:ELIC)
Sweden · Delayed Price · Currency is SEK 2.505
-0.090 (-3.47%)
Jul 24, 2026, 5:29 PM CET
Elicera Therapeutics AB Revenue
Elicera Therapeutics AB had revenue of 10.64M SEK in the twelve months ending March 31, 2026, up 146.66% year-over-year. In the year 2025, Elicera Therapeutics AB had annual revenue of 10.86M with 52.28% growth.
Revenue (ttm)
10.64M
Revenue Growth
+146.66%
P/S Ratio
15.72
Revenue / Employee
3.55M
Employees
3
Market Cap
167.17M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.86M | 3.73M | 52.28% |
| Dec 31, 2024 | 7.13M | -4.10M | -36.52% |
| Dec 31, 2023 | 11.23M | 9.95M | 777.23% |
| Dec 31, 2022 | 1.28M | 1.28M | 217,987.39% |
| Dec 31, 2021 | 587.00 | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 750.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRLAB Therapeutics AB | 92.46M |
| Xbrane Biopharma AB | 83.30M |
| Nanologica AB | 31.83M |
| Alzinova AB | 25.66M |
| Biovica International AB | 13.49M |
| NextCell Pharma AB | 9.24M |
| Xintela AB | 2.59M |
| Simris Group AB (PUBL) | 1.88M |
Elicera Therapeutics AB News
- 3 months ago - Elicera Therapeutics AB Quarterly report: Q1 2026 - Filings
- 5 months ago - Elicera Therapeutics AB Quarterly report: Q4 2025 - Filings
- 5 months ago - Elicera Therapeutics AB Annual report: Q4 2025 - Filings
- 9 months ago - Elicera Therapeutics AB Quarterly report: Q3 2025 - Filings
- 11 months ago - Elicera Therapeutics AB Quarterly report: Q2 2025 - Filings